N/A N=171 Medical Arm of the Interagency Registry for Mechanically Assisted Circulatory Support
Heart Failure · Systolic Heart Failure
Primary: Number of Heart Failure Participants Deceased at 24 Months — 43 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=172 Opioid Analgesia for MAB
MAB · Pain
Primary: Overall Maximum Self-reported Pain Score — 8; 8 units on a scale
N/A N=1,238,835 Improving BP Control in Diverse Populations Using BP MAP
Hypertension
Primary: Change in Blood Pressure Control, % of Patients — 2.8; 1.6; -0.4 percentage of patients
N/A N=60 The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease
Breast Abnormalities
Primary: Specificity of MBI. Specificity is Defined as the Number of True Negatives/ Total Number of Negative Pathology Results. — 27 lesions
Phase 4 N=545 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With an Adverse Event (AE) - Overall Summary — 67.4; 5.8; 20.2; 0.2 percentage of participants
N/A N=47 The Momba Mobile Application-based Community
Mental Health Wellness 1
Primary: Phone Retention — 9; 15; 14; 9 Participants — p=0.15
N/A N=630 Maternal Adversity, Vulnerability and Neurodevelopment
Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse) · Infant Development · Infant Behavior
Primary: Child's Cognitive Development Measured Using the Bayley Scales of Infant Development II. — 524; 508; 458; 422 Participants
Phase 2 N=16 A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients
Intracerebral Hemorrhage
Primary: Modified Rankin Scale — 3.5; 3.7 units on a scale
Phase 2 N=51 TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals
HIV-1-infection
Primary: Safety of TMB-365 and TMB-380 Given Intravenously (Sentinel and Core) — 0; 0; 0; 0 Participants
Phase 2 N=72 ACAM 3000 MVA at Harvard Medical School
Smallpox
Primary: Number of Participants Reporting Moderate or Greater Solicited Local Reactions — 3; 0; 1; 6 Participants
N/A N=47 Stage I Randomized Trial of Mentalization-Based Therapy for Substance Using Mothers of Infants and Toddlers
Maternal Substance Use · Child Abuse and Neglect
Primary: Maternal Capacity for Reflective Functioning (Assessed With the Parent Development Interview) — 3.59; 3.08; 3.54; 3.47 units on a scale
Phase 2 N=48 A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Mantle Cell Lymphoma
Primary: Number of Participants Achieving Complete Remission (CR) (Including Unconfirmed CR [CR(u)]) or Partial Remission (PR) — 19; 8 participants
N/A N=7,993 Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients
Hypertension
Primary: Percentage of Non-Diabetic and Diabetic Participants Meeting Blood Pressure Targets at 3 Months — 56.0; 28.2 percentage of participants
N/A N=339,902 Active Bathing to Eliminate Infection (ABATE Infection) Trial
Healthcare Associated Infections · Methicillin Resistant Staphylococcus Aureus · Multi Drug Resistant Organisms
Primary: MRSA and VRE Clinical Cultures — 0.87; 0.79 Hazard Ratio (Intervention vs Baseline) — p=0.17
Phase 2 N=6 Anti-malaria MAb in Malian Children
Plasmodium Falciparum Infection · Malaria
Primary: Participants With Local Adverse Events (AEs) - Year One — 3; 1; 0; 0 Participants
Phase 3 N=140 MabionCD20 Compared to MabThera in Lymphoma Patients
Diffuse Large B-Cell Lymphoma
Primary: Area Under the Serum Concentration-time Curve From Day 1 to Week 4 (AUC[1-4]) — 1559.51; 1509.79 (μg*day)/mL
Phase 3 N=232 A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.
Rheumatoid Arthritis
Primary: Number of Participants With Any Adverse Event, Any Serious Adverse Event, and Death — 189; 12; 0 participants
Phase 2 N=13 Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Stem Cell Mobilization Success Rate With Cytarabine and Rituximab — 4 Participants
N/A N=40 Safety of Microporous Annealed Particle (MAP) Wound Matrix in Patients With Clean Surgical Wounds.
Wound Heal
Primary: Incidence of Serious Adverse Device Effects in the Treatment Group Compared to the Control Group. — 0; 0 Participants
Phase 4 N=10 A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.
Rheumatoid Arthritis
Primary: Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score — 3.4; 2.3…
Phase 2 N=150 Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Lung Cancer · Non Small Cell Lung Carcinoma
Primary: Number of Participants With Objective Response Assessed by Independent Review Committee — 2; 8; 1 participants
Phase 3 N=1,604 Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation
Trauma Injury
Primary: Number of Participants With Mortality From Any Cause — 201; 192 Participants
N/A N=10 Mobile After-Care Intervention to Support Post-Hospital Transition (MACS)
Psychotic Disorders
Primary: Client Satisfaction Questionnaire (CSQ) — 19.2 units on a scale
Phase 4 N=36 A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score Based on 28-Joint Count (DAS28) — 5.51; 4.39; -1.12 scores on a scale — p=<0.0001
Phase 3 N=165 Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis
Cirrhosis
Primary: Mortality From Liver Failure — 11 participants
Phase 2 N=98 Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
Mild Cognitive Impairment · MCI · Aging
Primary: fMRI Measurement — 2267.0; 1491.23; 673.31; 989.19 voxels
N/A N=80 Mobile Application for Prescription Drug-Abuse Education (MAPDE)
Prescription Drug Abuse (Not Dependent)
Primary: Current Opioid Misuse Measure (COMM) — .72; .71; .62; .63 score on a scale — p=.72
Phase 3 N=129 A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
Primary: Number of Participants With Sputum Culture Conversion in Mycobacteria Growth Indicator Tube (MGIT) at Week 24 — 3; 16 Participants — p==0.002
Phase 2 N=49 Safinamide for Multiple System Atrophy (MSA)
Multiple System Atrophy
Primary: TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) — 52; 28; 49; 21 events
Phase 2 N=140 MEtronomic TrEatment Option in Advanced bReast cAncer
Breast Cancer
Primary: Time to Treatment Failure (TTF) Compared Between Treatment Groups. — 5.7; 8.3 months